Flowchart of identified studies, included studies and reasons for exclusion.

<p>Flowchart of identified studies, included studies and reasons for exclusion.</p

Predicted one year mortality by average imputed* CD4 count at antiretroviral therapy initiation assuming no mortality among those lost to follow-up with mortality expressed using a) an unlogged axis and b) a natural log axis.

<p>* 1000 imputations were used for each analysis.</p

Estimated mortality over the first year on antiretroviral therapy as a function of baseline CD4 count and assumptions about mortality among those lost to follow-up using beta distributions to impute CD4 counts that were a) uniformed by sample size and b) informed by sample size.

<p>Estimated mortality over the first year on antiretroviral therapy as a function of baseline CD4 count and assumptions about mortality among those lost to follow-up using beta distributions to impute CD4 counts that were a) uniformed by sample size and b) informed by sample size.</p

Predicted one year mortality by average imputed CD4 count at antiretroviral therapy initiation assuming a changing mortality among those lost to follow-up depending on CD4 count at ART initiation.

<p>Predicted one year mortality by average imputed CD4 count at antiretroviral therapy initiation assuming a changing mortality among those lost to follow-up depending on CD4 count at ART initiation.</p

Predicted one year mortality by average imputed CD4 count* at antiretroviral therapy initiation assuming 60% mortality among those lost to follow-up with mortality expressed using a) an unlogged axis and b) a natural log axis.

<p>* 1000 imputations were used for each analysis.</p

Estimation strategy.

<p>Estimation strategy.</p

Characteristics of 20 studies included in the meta-analysis of the relationship between baseline CD4 count and first year mortality on antiretroviral therapy.

#<p>Full citations given in Appendix S2 in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0069300#pone.0069300.s001" target="_blank">File S1</a>.</p>*<p>Denotes mean not median.</p

Study subject recruitment and inclusion for analysis.

<p>Study subject recruitment and inclusion for analysis.</p

Reference probability and marginal effects of experiencing pain or fatigue during the previous week (logistic regression, population averaged model).

<p>*Reference case is a female subject age 30–39, 1–30 days on ART.</p>a<p>Indicates p-value ≤0.05 for Wald test that marginal effect equals marginal effect for 271–360 days on ART.</p>b<p>Indicates p-value >0.05 for Wald test that marginal effect equals marginal effect for 271–360 days on ART.</p

Probability of not feeling well on day prior to interview by time on ART.

<p>Probability of not feeling well on day prior to interview by time on ART.</p